Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320775 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00320775 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT00320775, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
Interventions
- DRUG VEGF Trap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320775
The ClinicalTrials.gov registry entry for NCT00320775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap is the first listed.
NCT00320775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320775 about?
NCT00320775 is a clinical study titled "Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD". The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
What is the current status of trial NCT00320775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2005-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00320775?
The interventions under investigation include: VEGF Trap (DRUG).
Who is sponsoring clinical trial NCT00320775?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.